Cargando…

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder

The α(2)-adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez-Raga, Jose, Knecht, Carlos, de Alvaro, Raquel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455846/ https://www.ncbi.nlm.nih.gov/pubmed/26064054 http://dx.doi.org/10.2147/NDT.S65735

Ejemplares similares

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
por: Huss, Michael, et al.
Publicado: (2016)

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
por: Joseph, Alain, et al.
Publicado: (2017)

Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial
por: Stein, Mark A., et al.
Publicado: (2015)

Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Sikirica, Vanja, et al.
Publicado: (2012)

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology
por: Sikirica, Vanja, et al.
Publicado: (2013)

A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice
por: van Stralen, Judy, et al.
Publicado: (2021)

Attention deficits following ADEM ameliorated by guanfacine
por: Singh-Curry, Victoria, et al.
Publicado: (2010)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
por: Erder, M. Haim, et al.
Publicado: (2013)

Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada
por: Lachaine, Jean, et al.
Publicado: (2019)

Efficacy and safety of guanfacine extended‐release in Japanese adults with attention‐deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double‐blind, placebo‐controlled study
por: Naya, Noriyuki, et al.
Publicado: (2020)

Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy
por: Ota, Toyosaku, et al.
Publicado: (2021)

Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
por: Lachaine, Jean, et al.
Publicado: (2016)

Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended‐release tablets
por: Inoue, Yuji, et al.
Publicado: (2019)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)
por: Sagvolden, Terje
Publicado: (2006)

Treatment of Children and Adolescents with Attention Deficit Hyperactivity Disorder and/or Tourette's Disorder with Clonidine Extended Release
por: Joo, Sung Woo, et al.
Publicado: (2018)

Weight and Height in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Longitudinal Database Study Assessing the Impact of Guanfacine, Stimulants, and No Pharmacotherapy
por: Schneider, Gary, et al.
Publicado: (2019)

Efficacy and Safety of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder
por: Childress, Ann C., et al.
Publicado: (2018)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder
por: Pliszka, Steven R., et al.
Publicado: (2017)

Lisdexamfetamine in combination with guanfacine as an effective treatment in the management of behavioral disturbances in patients with Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Case report
por: Del Sol Calderon, P., et al.
Publicado: (2023)

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents
por: Bello, Nicholas T
Publicado: (2015)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders
por: Ming, Xue, et al.
Publicado: (2011)

Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder
por: Wigal, Sharon B., et al.
Publicado: (2017)

Multiple Intelligences Profiles of Children with Attention Deficit and Hyperactivity Disorder in Comparison with Nonattention Deficit and Hyperactivity Disorder
por: Najafi, Mostafa, et al.
Publicado: (2017)

Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder
por: Owens, Judith, et al.
Publicado: (2016)

Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists
por: Caballero, Joshua, et al.
Publicado: (2017)

Case Report: Guanfacine and methylphenidate improved chronic lower back pain in autosomal dominant polycystic kidney disease with comorbid attention deficit hyperactivity disorder and autism spectrum disorder
por: Kasahara, Satoshi, et al.
Publicado: (2023)

Comorbidity of attention deficit hyperactivity disorder with personality disorders in homeless people
por: Salavera, Carlos, et al.
Publicado: (2014)

Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidate
por: van der Schans, Jurjen, et al.
Publicado: (2015)

Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder
por: Teuscher, Nathan S, et al.
Publicado: (2015)

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day
por: Faraone, Stephen V., et al.
Publicado: (2023)

Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”
por: Price, Maxwell Z., et al.
Publicado: (2023)

Personality Profile of Parents of Children with Attention Deficit Hyperactivity Disorder
por: Dadashzadeh, Hossein, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rfeakhe32kppnh7n90c13sk0b3